Article
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Hepatology (Baltimore, Md.) - 1 Jun 2017
Lawitz Eric, Poordad Fred, Wells Jennifer, Hyland Robert H, Yang Yin, Dvory-Sobol Hadas, Stamm Luisa M, Brainard Diana M, McHutchison John G, Landaverde Carmen, Gutierrez Julio
Abstract excerpt
The optimal retreatment strategy for hepatitis C virus (HCV) genotype 1-infected patients who fail direct-acting antiviral (DAA)-based regimens remains unknown. In this phase 2, open-label study conducted at a single center in the United States, patients with HCV genotype 1 infection who previously failed to achieve sustained virological response (SVR) on a DAA-based regimen were randomized to receive treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.